Clinical trials: Lymphnode Metastasis
Immunotherapy
Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones
Most of HLA-A2 melanomas express Melan-A/MART-1 antigen and are recognized by tumor reactive Melan-A specific T lymphocytes. By using blood samples from HLA-A2 melanoma patients (stage III and IV), our goal is to produce a tumor…
- Trial name
- NCT00720031
- Testing
- autologous Melan-A/MART-1 specific CTL clones
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Nantes University Hospital
Thyroid Papillary Carcinoma
A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma
To establish and validate a suitable and practical nomogram for primary hospitals to predict the risk of central lymph node metastasis (CLNM) among thyroid papillary carcinoma (PTC) patients based on clinical and ultrasound…
- Trial name
- NCT05191927
- Testing
- male
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lymphadenopathy, Lymphnode Metastasis
Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
Lymph nodes are one of the most important components of the human immune system, and superficial lymph node enlargement lacks specificity.
- Conditions
- Lymphadenopathy, Lymphnode Metastasis, Lymphoma, Lymphatic Tuberculosis
- Trial name
- NCT07155954
- Testing
- SRUS imaging of the lymph nodes before surgery or biopsy
- Where
- China
- Volunteers
- 779 people
- Sponsor
- Peking University Third Hospital
Melanoma (Skin)
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III…
- Trial name
- NCT00002763
- Testing
- recombinant interferon alfa
- Where
- 86 sites in Austria, Belgium and 19 more
- Volunteers
- 1,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
NSCLC (Non-small Cell Lung Cancer), Artificial Intelligence (AI)
Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer
This nationwide, multicenter observational study aims to develop and validate a multimodal artificial intelligence (AI) model for detecting occult lymph node metastasis in early-stage non-small cell lung cancer (NSCLC) patients.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Artificial Intelligence (AI), Lymphnode Metastasis
- Trial name
- NCT06684418
- Testing
- chest enhanced CT
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Fudan University
High-risk Prostate Cancer, Prostate Cancer
Ga-68-PSMA-11 in High-risk Prostate Cancer
This will be an open-label, single-arm, rater-blinded, multicenter, diagnostic phase 1/2 study to assess safety and diagnostic performance of Ga-68-PSMA-11 positron emission tomography / computer tomography (PET/CT) imaging to…
- Conditions
- High-risk Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic, Lymphnode Metastasis
- Trial name
- NCT03362359
- Testing
- Ga-68-PSMA-11
- Where
- 8 sites in Austria, Germany
- Volunteers
- 173 people
- Sponsor
- German Cancer Research Center